A convergent research team composed of researchers from Seoul National University, Ajou University, CHA University, and Yonsei University has succeeded in developing a new drug based on targeted protein degradation technology (PROTAC).
On the 5th, Seoul National University announced, "The convergent research team successfully developed an MDM2 (bone differentiation inhibitor) targeted PROTAC that can induce bone regeneration by applying PROTAC technology to the field of regenerative therapy for the first time."
They added, "Transcriptome analysis for in-depth evaluation of drug efficacy confirmed that the MDM2-targeted PROTAC significantly increased the expression of genes related to bone formation compared to existing MDM2 inhibitor drugs," and "the developed drug also demonstrated a strong bone regeneration-inducing effect."
PROTAC is attracting attention as an innovative therapeutic strategy because it can target proteins that are difficult to regulate with conventional drugs. This study is evaluated as overcoming the limitations of PROTAC, which had so far been used only as a candidate for anticancer drugs, and was published in 'Advanced Science,' a top international journal in the field of convergent research.
A Seoul National University official said, "This research achievement greatly contributed to expanding the application range of PROTAC technology to the field of regenerative medicine," and "it is expected to be utilized as an innovative and new strategy in the development of bone regeneration therapeutics in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
